2025-02-20
Global Second PD-L1 ADC: Henlius’ HLX43, a Novel PD-L1 ADC, Advances to Phase 2 Clinical Trials with First Patient Dosed
Global biopharmaceutical company Henlius aims to greatly improve patient well-being with affordable and innovative biologic medicines
Generics Bulletin
Nature Research
GEN Exclusives
BIOPHARMA DIVE